Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Barón, M. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barón, M. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 5:323-327, 1994
© 1994 European Society for Medical Oncology

research-article

Comparison of two chemotherapeutic regimens – mitomycin + vindesine 4-cisplatin (MVP) vs. mitomycin + ifosfamide + cisplatin (MIP) – in advanced non-small-cell lung cancer

M. González Barón1, J. Feliu1,, E. Espinosa1, C. García Girón4, E. Blanco5, P. Garrido2, A. Colmenarejo3, A. Ordóñez1, A. Moyano2, I. de la Gándara1, P. Zamora1 and ONCOPAZ Cooperative Group

1Dept. of Medical Oncology Hospital La Paz Madrid
2Dept. of Medical Oncology Hospital Ramón y Cajal Madrid
3Dept. of Medical Oncology Hospital Militar del Aire Madrid
4Dept. of Medical Oncology Hospital General Yague Burgos
5Dept. of Medical Oncology Hospital Infanta Cristina Badajoz, Spain

Correspondence to: J. Feliu, M.D., Servicio de Oncologia Medica, Hospital La Paz, Paseo de la Castellana, 261, 28046, Madrid, Spain

BACKGROUND:: A prospectively randomized trial was performed to compare the efficacy and toxicity of two chemotherapeutic regimens widely used in advanced non-small-cell lung cancer (NSCLC).

PATIENTS AND METHODS:: From January 1989 to March 1992, 196 patients with measurable disease were included in the trial. Ninety-three patients received mitomycin-vindesine-cis-platin (MVP) and 94 mitomycin-ifosfamide-cisplatin (MIP).

RESULTS:: The objective response rate (complete plus partial remissions) was 28% (26/93 patients, 95% confidence interval 20%–40%) in the MVP arm and 30% (28/94 patients, 95% confidence interval 20.5%–40%) in the MLP arm. The median survival was 8.5 and 9 months, respectively. Neither the response rates nor the median survivals were significantly different. Grade III-IV leukopenia was more frequent with MVP (13% vs. 2% of the courses, p<0.001), as well as grade I-II neurologic toxicity (30% vs. 6%, p<0.001). In contrast, grade I-II anemia and grade I-II urologic toxicity were more frequent with MIP (7% vs. 25%, p<0.001 and 1% vs. 11%, respectively).

CONCLUSION:: Given the low efficacy of both schemes in the treatment of advanced NSCLC, their use cannot be recommended outside of clinical trials.

non-small-cell lung cancer, chemotherapy, response, toxicity


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.